PUBLICATIONS, NEWS & EVENTS
32nd Annual North American Cystic Fibrosis Conference (NACFC) 18-20 October-Denver – Submission 210
Submission: 210 - PHARMACOKINETIC AND PHARMACODYNAMIC PROFILE…
September 28, 2018/by admin32nd Annual North American Cystic Fibrosis Conference (NACFC) 18-20 October-Denver – Submission 89
Submission: 89 - IDENTIFYING PATHWAYS REGULATING GOBLET CELL…
September 28, 2018/by adminEnterprise Therapeutics raises £29 million ($41 million USD) funding
Brighton, UK – 12 April 2018: Enterprise Therapeutics Ltd (Enterprise),…
April 12, 2018/by adminBuilding in vivo potency and duration of action and into a novel inhaled ENaC blocker, ETD001, presented at the European Cystic Fibrosis Society Basic Science Meeting, Loutraki, Greece, March 2018
Inhaled drugs are typically cleared very rapidly from the airway…
March 2, 2018/by adminIdentifying pathways regulating goblet cell metaplasia: phenotypic screening with bronchospheres, presented at the European Cystic Fibrosis Society Basic Science Meeting, Loutraki, Greece, March 2018
It is widely accepted that the composition of mucus in the CF…
March 1, 2018/by adminThe discovery of novel regulators of airway anion secretion, oral communication at the UK Cystic Fibrosis Trust Conference, Nottingham, UK, September 2017
September 1, 2017/by adminThe discovery of potentiators of the calcium activated chloride channel, TMEM16A, oral communication at the Cystic Fibrosis Foundation Research Conference, Stevenson, USA, June 2017
June 1, 2017/by adminEnterprise Therapeutics receives funding from Cystic Fibrosis Trust
Award will support research into the use of bronchosphere technology…
April 5, 2017/by adminThe discovery of novel TMEM16A potentiator compounds, presented at the Gordon research Conference, “Mucus & Mucociliary interactions”, Galveston, USA, February 2017
It is widely accepted that the composition of mucus in the CF…
February 1, 2017/by adminEnterprise Therapeutics Announces £4 million ($5 million USD) Fundraising
Brighton, UK – 10th November, 2016: Enterprise Therapeutics…
November 10, 2016/by adminEnterprise Therapeutics appoints Dr John Ford as CEO
Brighton, UK – October 17, 2016 - Enterprise Therapeutics Ltd,…
October 17, 2016/by adminFlagellin-induces a hypersecretory phenotype in primary human bronchial epithelial cells, presented at North America Cystic Fibrosis Conference, Orlando, October 2016
The TLR5-agonist flagellin (FLG) is the key protein component…
October 1, 2016/by admin
